Navigation Links
Prasco® Launches Authorized Generic of Shire's Carbatrol®
Date:1/12/2012

CINCINNATI, Jan. 12, 2012 /PRNewswire/ -- Prasco® Laboratories announced today it has entered into an agreement with Shire (NASDAQ: SHPGY) for the distribution in the U.S. of the Authorized Generic version of Carbatrol® (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths.

Carbamazepine Extended-Release Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol®. The product will be distributed in the U.S. under the Prasco label. Financial terms of the agreement were not disclosed.

"We are pleased to provide Carbamazepine Extended-Release Capsules to pharmacists and consumers," said Prasco chief executive officer Christopher H. Arington. "As a Prasco Authorized Generic, Carbamazepine Extended-Release Capsules will provide patients with a therapeutically equivalent product to the brand."

Indications

Carbatrol is a medicine used to treat:

  • certain types of seizures (partial, tonic-clonic, mixed).
  • certain types of nerve pain (trigeminal and glossopharyngeal neuralgia).

Carbatrol is not a regular pain medicine and should not be used for aches or pains.

Important Safety Information

Do not stop taking Carbatrol without first talking to your doctor. Stopping Carbatrol suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus).

WARNING

SERIOUS SKIN REACTIONS

Carbatrol may cause rare but serious rashes that may lead to death. These serious skin reactions are more likely to happen within the first four months of Carbatrol treatment but may occur at later times
'/>"/>

SOURCE Prasco Laboratories
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
2. Prasco® Launches Authorized Generic with Shionogi Inc.
3. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
4. MX.com Launches Pelvic Health Program Model to Help Hospitals Rapidly Expand Key Services
5. Shopko Launches Mobile Pharmacy App to Maximize Customer Convenience
6. QIAGEN Launches QIAensemble Decapper Sample Preparation Automation System
7. Revation Systems Launches an Accessible Virtual Care Solution for Healthcare Organizations
8. Verenium Launches Second Enzyme Product for Oilfield Services
9. Successful Diabetes Product Launches Balance Digital & Traditional Public Relations Tools
10. Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity
11. theVisualMD Launches a Revolutionary New Visual Path to Wellness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Abaxis, Inc. (NasdaqGS: ABAX), a medical ... that Martin Mulroy , chief commercial ... & Veterinary Conference on Wednesday, May 29, 2013 at ... Le Parker Meridien Hotel in New York ... Abaxis develops, manufactures, markets and sells portable blood analysis ...
(Date:5/21/2013)...  BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC ... stem cell based therapies for various personal applications, announced ... and CEO, will be presenting at the Marcum MicroCap ... on Thursday, May 30, 2013 at the Grand Hyatt ... York City.  Mr. Weinreb,s presentation will take place at ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
... S.C., Oct. 21, 2011 Federal, state and local ... growing biomedical research effort with the dedication of a ... for major diseases. The complex, housing 78 ... traditional research approach by combining scientists from different fields ...
... division of Sanofi (EURONEXT: SAN and NYSE: ... study evaluating the immunogenicity and safety of an investigational ... of age and older. Currently licensed influenza vaccines target ... a given year. The data were presented at the ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 2Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 3Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 4Sanofi Pasteur Presents Additional Data on Investigational Quadrivalent Influenza Vaccine 5
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker ... the rights of victims injured by defective medical devices, ... Bone & Joint Surgery on May 15, 2013. The ... used to identify complications that occur in patients with ... of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) , ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
(Date:5/21/2013)... Adenotonsillectomy, or the removal of the adenoids and tonsils, ... States, often as a treatment for children with obstructive ... a child,s attention and executive functioning, behavior, sleep apnea ... evaluated until now. A study led by Susan ... Sleep and Cardiovascular Medicine and Associate Clinic Director of ...
Breaking Medicine News(10 mins):Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2
... and other headaches are more likely to have retinopathy, damage ... severe vision problems or blindness, than those without a ... May 15, 2007, issue of Neurology, the scientific journal of ... researchers reviewed the headache history and eye health of 10,902 ...
... and chronic obstructive pulmonary disease among men has discovered ... progressive inflammatory lung disease (COPD). ,COPD (chronic ... progressive lung disease, such as emphysema and bronchitis. ... 43,000 men, who were already part of the US ...
... of infant mortality, cancer, accidental death, and diabetes than any ... according to a state health official, the Sioux Falls Argus ... Health Department, at the request of the Zaniya Task Force, ... of the state's population and found what he called "very ...
... increase the risk of heart attacks and death in patients who ... caused by plaque build-up on the inside walls of the arteries ... them to harden and narrow. This in addition, can ... , According to a report in the Journal of ...
... new research has found that extremely anxious patients with heart ... death when compared to those with a calmer attitude ... were in greatest danger, while those who initially had high ... risk. ,"Most patients come in very anxious about ...
... lay along the Nile in ancient Egypt and not ... the KNH Centre for Biomedical Egyptology at the ... team discovered the evidence in medical papyri written in ... ,"Classical scholars have always considered the ancient Greeks, ...
Cached Medicine News:Health News:Mid-Life Headaches May Increase Risk of Vision Problems 2Health News:American Indians in South Dakota Have More Health Problems Than Others in State, Nationwide, Health Official Says 2Health News:Dont Worry- Be Good To Your Heart 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 2Health News:Risk of Heart Attack, Death High Among Extremely Anxious Patients 3Health News:Modern Medicine Originated in Egypt, Not Greece 2
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: